Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study
eClinicalMedicine · 2024-01 · 67 · 102403
DOI: 10.1016/j.eclinm.2023.102403 ↗Kurz gefasst
Fachartikel in der Zeitschrift eClinicalMedicine, 2024-01. Verfasst von Xingxiang Pu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South Universit…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Texas MD Anderson Cancer Center, Chinese Academy of Medical Sciences, Jiangsu Hengrui Pharmaceuticals Co Ltd.
Abstract (Originalsprache)
Background
Platinum-doublet chemotherapy plus immunotherapy has been the standard of care for the first-line treatment of advanced non-small cell lung cancer lacking actional driver mutations. However, optimization of drug combinations is still needed to find a better balance between therapeutic efficacy and safety in the immunotherapy era. We aimed to investigate the efficacy and safety of platinum-free albumin bound paclitaxel (nab-paclitaxel) combined with camrelizumab and apatinib as first-line treatment for patients with advanced lung adenocarcinoma.
Methods
In this multicenter open-label, single-arm phase II trial, patients with systemic treatment-naïve advanced lung adenocarcinoma without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations received a rational-based combination of camrelizumab (200 mg intravenously, day one), apatinib (250 mg, q.d., five continuous days per week), and nab-paclitaxel (135 mg/m2 intravenously, days one and eight) every three weeks for four to six cycles in China. Patients with controlled disease were maintained with camrelizumab and apatinib. The primary end point was progression-free survival (PFS). This trial is registered with ClinicalTrials.gov (No. NCT04459078).
Findings
Between August 26, 2020 and May 20, 2022, 64 patients were enrolled. The median PFS was 14.3 (95% CI: 9.9, not reached) months. The confirmed objective response rate was 64.1% (95% CI: 51.1, 75.7). The grade 3-4 hematologic treatment-related adverse events (TRAEs) were decreased neutrophil count (14.1%), decreased white blood cell count (7.8%), and anemia (3.1%). The most common non-hematologic TRAEs of grade 3-4 were increased alanine transaminase (18.8%) and aspartate transaminase (15.6%). No treatment-related death occurred. The quality of life was on average not clinically meaningful worse through treatment cycle 14.
Interpretation
Nab-paclitaxel plus camrelizumab and apatinib showed clinically meaningful anti-tumor activity and manageable safety, with few hematologic toxicities, and might be a potential treatment option in patients with advanced lung adenocarcinoma lacking EGFR/ALK mutations. Funding: Heath Research Foundation of Chinese Society of Clinical Oncology, Hunan Provincial Natural Science Foundation of China, Hunan Cancer Hospital Climb Plan, Sister Institution Network Fund of The University of Texas MD Anderson Cancer Center, The Science and Technology Innovation Program of Hunan Province, and Suzhou Sheng Diya Biomedical Co., Ltd, a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Shanghai, China).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410000, China.
- Department of Thoracic Medical Oncology, Fujian Cancer Hospital, Fuzhou 350014, China.
- Department of Medical Oncology, Hunan Province Directly Affiliated TCM Hospital, Zhuzhou 412000, China.
- Department of Oncology, The Second Affiliated Hospital of Kunming Medical University, Yunnan 650108, China.
- Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
- Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, Shenzhen YuceBio Technology Co., Ltd, Shenzhen 518000, China.
Förderung
- University of Texas MD Anderson Cancer Center
- Chinese Academy of Medical Sciences
- Jiangsu Hengrui Pharmaceuticals Co Ltd
- Natural Science Foundation of Hunan Province
Zitieren
APA
Pu, X., Lin, G., Xiao, M., Lin, J., Wang, Q., Kong, Y., Yan, X., Xu, F., Xu, Y., Li, J., Li, K., Chen, B., Wen, X., Tan, Y., Cheng, F., Zhu, K., Li, N., & Wu, L. (2024). Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study. eClinicalMedicine, 67, 102403. https://doi.org/10.1016/j.eclinm.2023.102403
Vancouver
Pu X, Lin G, Xiao M, Lin J, Wang Q, Kong Y, et al. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study. eClinicalMedicine. 2024;67:102403. doi:10.1016/j.eclinm.2023.102403
BibTeX
@article{Pu2024,
author = {Pu, Xingxiang and Lin, Gen and Xiao, Maoliang and Lin, Jie and Wang, Qianzhi and Kong, Yi and Yan, Xuejun and Xu, Fang and Xu, Yan and Li, Jia and Li, Kang and Chen, Bolin and Wen, Xiaoping and Tan, Yali and Cheng, Fengzhuo and Zhu, Kangle and Li, Na and Wu, Lin},
title = {Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study},
journal = {eClinicalMedicine},
year = {2024},
volume = {67},
pages = {102403},
doi = {10.1016/j.eclinm.2023.102403}
}
EUVIMED